KemPharm (NASDAQ:KMPH) has been assigned a $11.00 price objective by analysts at Oppenheimer in a research report issued to clients and investors on Thursday, September 20th. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 331.37% from the stock’s previous close.
Several other analysts have also recently weighed in on the company. Zacks Investment Research raised KemPharm from a “sell” rating to a “hold” rating in a report on Thursday, July 12th. Janney Montgomery Scott began coverage on KemPharm in a report on Wednesday, May 23rd. They issued a “buy” rating and a $17.00 price target on the stock. Cowen cut KemPharm from an “outperform” rating to a “hold” rating in a report on Monday, July 9th. ValuEngine raised KemPharm from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 29th. Finally, Canaccord Genuity set a $11.00 price objective on KemPharm and gave the company a “buy” rating in a report on Thursday, May 24th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $10.50.
Shares of NASDAQ:KMPH remained flat at $$2.55 on Thursday. The company’s stock had a trading volume of 332,549 shares, compared to its average volume of 170,978. KemPharm has a 1 year low of $2.46 and a 1 year high of $8.40. The stock has a market cap of $77.00 million, a PE ratio of -0.86 and a beta of -0.31. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of -1.05.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.31. As a group, equities analysts expect that KemPharm will post -2.95 earnings per share for the current fiscal year.
In other news, major shareholder Delaware Street Capital Master acquired 2,000,000 shares of the firm’s stock in a transaction that occurred on Friday, October 5th. The shares were bought at an average cost of $3.00 per share, with a total value of $6,000,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have purchased 2,313,933 shares of company stock worth $7,242,003. 25.90% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in KMPH. Millennium Management LLC purchased a new position in KemPharm in the 1st quarter worth approximately $122,000. Spark Investment Management LLC purchased a new position in KemPharm in the 2nd quarter worth approximately $176,000. Royal Bank of Canada increased its stake in KemPharm by 1,847.1% in the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after purchasing an additional 22,886 shares during the period. Change Path LLC purchased a new position in KemPharm in the 1st quarter worth approximately $479,000. Finally, JPMorgan Chase & Co. increased its stake in KemPharm by 15,976.2% in the 1st quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock worth $795,000 after purchasing an additional 100,011 shares during the period. 39.15% of the stock is currently owned by institutional investors.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.